Will Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?

Merck’s Gardasil sales fell 22% to $1.07 billion in Q1 2026, pressured by weak demand in China and Japan, and management does not expect improvement in 2026. Merck temporarily halted Gardasil shipments in China to work down elevated inventory at partner Zhifei. Offsetting some of the weakness, Capvaxive sales rose 31% year over year, while Enflonsia generated just $1 million in Q1 and is expected to remain minimal in Q2.

Analysis

The key market issue is not the near-term Gardasil print itself, but the signaling effect: Merck is conceding that one of its few non-oncology growth pillars is now facing a multi-quarter reset in the two ex-U.S. channels that mattered most for volume absorption. That creates a second-order drag on perceived quality of MRK’s earnings base, because the market will likely start discounting the durability of its vaccine franchise more broadly, not just the HPV line. In that setting, the stock’s year-to-date outperformance looks vulnerable if investors begin marking down 2026–27 consensus as a pipeline of modest offsets rather than a clean reacceleration story.

The more important competitive read-through is that inventory destocking in China and soft demand in Japan likely suppresses reorder patterns across the category, which can temporarily flatter rivals’ shares while still hiding true end-demand weakness. That makes AZN, SNY, PFE, and GSK look comparatively insulated in the near term because RSV and pneumococcal franchises are being driven by launch cadence and seasonality, not a single channel overhang; however, if channel inventory normalization persists, the pricing and launch assumptions embedded in vaccine growth forecasts could prove too aggressive across the space. Capvaxive remains the clearest internal offset for Merck, but it is too small today to offset even a moderate Gardasil step-down, so MRK’s multiple should be more sensitive to any evidence that Capvaxive uptake is slowing.

The contrarian risk is that the market may be overreacting to a China-specific digestion phase and underestimating how quickly Gardasil could stabilize once inventory clears; the issue is less structural demand destruction than timing mismatch. But that recovery likely takes months, not weeks, and management’s own guidance implies no meaningful support in 2026, which removes the usual “buy the dip on normalization” argument. Near term, the cleaner catalyst is not a rebound in Gardasil but whether consensus starts cutting outside-year EPS as vaccine mix and launch offsets disappoint.

Key Decisions for Investors

• Short MRK vs long AZN in a 1:1 pair for the next 1-3 months; thesis is MRK consensus downside from vaccine weakness while AZN has cleaner near-term RSV and alliance revenue support. Cover if MRK management signals shipment normalization or if consensus stops drifting lower.
• Short MRK vs long SNY over 1-2 quarters; SNY has better relative insulation from a Gardasil-specific reset and should hold its multiple better if vaccine channel concerns broaden.
• Sell MRK call spreads 3-6 months out to monetize likely cap on upside until 2026 guidance stabilizes; prefer defined-risk upside shorts over outright puts because valuation is not extended enough for convex downside.
• Go long PFE or GSK only as a relative-value hedge against sector sentiment, not as a standalone directional bet; both can benefit if investors rotate toward RSV/pneumococcal names with more diversified launch narratives.
• Set a tactical buyback alert on MRK if the stock underperforms the sector by >5% on a downgrade wave but consensus EPS is cut less than 2%; that would suggest the move is overdone and offer a better entry for a medium-term mean reversion trade.